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Background: The sequence of the beta-subunit of human chorionic gonadotropin (hCGβ) varies depending on
whether hCGβ is encoded by type I or type II genes. Type II genes are upregulated in trophoblast and cancer
but hCGβ can be detected in the serum of nonpregnant women and healthy individuals. We aimed to determine
whethermonoclonal antibody (mAb) FBT11-II speciﬁcally detects hCGβ encoded by type II genes (type II hCGβ).
Methods:Competitive inhibition assayswith synthetic peptides, immunocytochemical and immunohistochemical
studies, type II hCGβ dosing immunoassays and sequencing of CGB genes were performed.
Results: Competitive inhibition assays determined thatmAb FBT11-II recognizes the type II hCGβ derived peptide.
CGBmRNA sequencingof JEG-3 (trophoblastic) and T24 (bladder) cell lines conﬁrmed that JEG-3 expresses type II
geneswhile T24 expresses exclusively type I. FBT11-II only recognizes JEG-expressed hCGβ. Placenta immunohis-
tochemical studies conﬁrmed that type II hCGβ expression is restricted to the syncytiotrophoblast. Immunoassays
detected type II hCGβ in serum of patients with either nontrophoblastic cancers or fetal Down syndrome.
Conclusion: Type II gene expression can be detected using FBT11-II. This speciﬁc recognition could improve the
clinical usefulness of assays aimed at either managing aggressive tumors or screening for Down syndrome.
© 2015 Institut Curie. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human chorionic gonadotropin (hCG) is a member of the glycopro-
tein hormone family, which also comprises LH, FSH, and TSH [1]. Theseimiques et Biologiques pour la
pharmacie, Université Paris
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V. This is an open access article undehormones share a common α-subunit of 92 amino acids that is non-
covalently associated with a hormone β-subunit. The β-subunit of
hCG (hCGβ) contains 145 amino acids. In addition to its expression by
trophoblastic cells during pregnancy, hCGβ is produced by normal
tissues of different histological origins and is expressed by gonadal
and nongonadal neoplasms [2,3]. While the hCG α-subunit (hCGα) is
encoded by one gene on chromosome 12q21.1-23 [4], hCGβ is encoded
by six non-allelic genes (CGB genes) clustered on chromosome 19q13.3
and named CGB1 or β1, CGB2 or β2, CGB3 or β3, CGB5 or β5, CGB7 or β7
and CGB8 or β8 [5–7]. Recent data show that the diversity of these genes
is one of the highest reported for human genes and that high interindi-
vidual and intergenic differences in expression exist [7,8]. Genes β1 and
β2 might encode a protein unrelated to hCG [9] while the remaining
four genes encode the same protein, with the exception of the β7r the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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posed to an aspartic acid in the other three genes [6,10,11]. On the basis
of the amino acid residues in position 117, genes encoding the hCGβ
subunit were classiﬁed as type I genes if they encoded an alanine (of
which only one exists: gene β7) or as type II genes if they encoded an
aspartic acid (of which three exist: β3, β5, β8) [12]. Numerous normal
nontrophoblastic tissues express preferentially type I gene, whereas,
in addition to type I gene, normal pituitary, testis and trophoblast as
well asmalignant trophoblastic andmalignant nontrophoblastic tissues
of different histological types express type II genes [2]. These differences
in expression offer the possibility of distinguishing between hCGβ
expressed by most normal nontrophoblastic tissues (i.e. type I) from
hCGβ produced only by normal trophoblast and by malignant cells
(i.e. type II).
Studies to differentiate between type I and type II genes have
concentrated on elegant techniques using molecular beacons or nested
PCR and are able to detect a single nucleotide difference at position 117,
i.e. GCC as opposed to GAC coding respectively for alanine or aspartic
acid [2,13]. However, depending upon the techniques employed,
different results were observed in tissues and in cell lines such as the
T24 cell line [2,13]. On the other hand, a speciﬁc antibody able to
distinguish between the free hCGβ subunits transcribed and translated
from either type I or type II genes has never been described: fusion
experiments using synthetic peptides analogous to the 114–122
region of hCGβ as immunogens and aimed at generating monoclonal
antibodies capable of distinguishing an aspartic acid from an alanine
at position 117 have been unsuccessful, at least in our laboratory.
In the present study, we show that mAb FBT11-II, which is speciﬁc
to free hCGβ and recognizes the nicked form of this subunit [14,15] is
capable of discriminating between hCGβ subunits encoded by type I and
type II genes. Interestingly, the ELSA-FbHCG immunoradiometric assay is
based on FBT11, the parental clone of FBT11-II, which suggests that this
assay only measures type II hCGβ expression. This result has an impact
on studies that use this assay since only hCG produced during either
pregnancy and malignant processes will be preferentially measured.
hCG produced by normal non-trophoblastic cells will be undetected.
2. Materials and methods
2.1. Subjects
Sera frompregnantwomenwith fetal Down syndrome (n=9)were
obtained from the serum library of Hopital Cochin, Paris. These blood
samples had been collected during the ﬁrst trimester of pregnancy.
Sera from patients with lung cancer (n = 30) or bladder cancer (n = 3)
were obtained from the serum library of Institut Curie, Saint-Cloud.
These blood samples had been collected according to protocols previously
approved by the human studies committee of each institution. An
informed consent had been obtained from each participant.
2.2. Cell lines
Human choriocarcinoma cell line JEG-3 was cultured in Eagle's
Minimum Essential Medium and human bladder carcinoma cell line
T24 was cultured in Dulbecco's MEM (4.5 g/l glucose). All media were
supplementedwith 10% fetal calf serumand1×penicillin–streptomycin
(Invitrogen, Cergy Pontoise, France). Cell culture supernatants from
conﬂuent JEG-3 or T24 cell lines were concentrated 10× using
amicon ultra-15 centrifugal ﬁlter units (nunc, Thermo Fisher Scientiﬁc,
Brebières, France).
2.3. Solid-phase peptide synthesis
Synthetic 7-mer peptides corresponding to residues 1 through 7 of
the hCGβ subunit were synthesized as previously described [16] by
the solid-phase method [17] in an Applied Biosystems Model 430 Apeptide synthesizer. The sequences of the peptides were as follows:
SKEPLRP (corresponding to residues 1 through 7 of hCGβ encoded by
type II genes β3, β5 and β8); SREMLRP (corresponding to residues
1 through 7 of hCGβ encoded by type I gene β7); and SREPLRP (corre-
sponding to residues 1 through 7 of the LHβ gene).
2.4. Antibodies
Monoclonal antibodies (mAbs) FB09, FB12 and FBT11-II were
obtained as previously described [16–18]. MAbs FB09 and FB12, elicited
against a synthetic peptide analogous to the COOH 109-145 terminal
portion (CTP) of hCGβ, are directed against the 134–140 and 110–116
regions, respectively [18]. These mAbs are speciﬁc for either hCG or its
hCGβ subunit and do not bind to LH or its LHβ subunit. MAb FBT11-II,
elicited against puriﬁed hCGβ subunit (CR 129), is directed to a discon-
tinuous epitope encompassing residues 1 through 7 and 82 through 92
of hCGβ [16]. FBT11-II is an IgG1 speciﬁc for the hCGβ subunit and does
not bind to hCG nor to LHwhile its cross reactivitywith the LHβ subunit
is of 0.6% [14,16]. Mouse IgG1 isotype control MG100 (Invitrogen, Cergy
Pontoise, France) was used as a control antibody. Polyclonal antibody
A0231 from Dako (Trappes, France) was raised against the isolated
beta-chain of hCG and reacts with free hCGβ and dimeric hCG.
2.5. Competitive inhibition assays with peptides
Competitive inhibition assays were performed as previously de-
scribed [16]. Brieﬂy, 125I labeled hCGβ, containing both type I and type
II hCGβ, (NIH-hCGβ (CR-125) labeled by the IODO-GEN method [19])
was employed as the tracer. All experiments were performed in
50 mM phosphate buffer, pH 7.5, containing 154 mM NaCl, 0.02%
sodium azide, and 1% bovine serum albumin. First, we determined
the dilution of FBT11-II which produced a 50% binding to 125I-hCGβ
(30,000 cpm) in the absence of peptide. Then, competitive inhibition
assays were performed with the deﬁned dilution of antibody. Brieﬂy,
displacement curves were generated in the presence of increasing
concentrations of unlabeled peptides as follows: 100 μl of 125I-hCGβ,
100 μl of monoclonal antibody, and 50 μl of the competitive inhibitor
(at increasing concentrations) were incubated simultaneously at 4 °C
for 18 h. The antigen–antibody complex was then precipitated by
adding normal human serum diluted (1:3) in phosphate buffer (100 μl)
and 1 ml of 20% polyethylene glycol. After centrifugation, radioactivity
of the pellet was measured. Dose–response curves showed a half-
maximal inhibitory dose for each molecule tested (ID50).
2.6. Sequencing
RNA obtained from human bladder carcinoma cell line T24 was
reverse-transcribed into cDNA with 400 units of SuperScript II RNase
H-reverse transcriptase (Life Technologies, California, USA). Twomicro-
liters of this cDNA was used for 35 cycles of polymerase chain reaction
(PCR) with 1.25 units of AmpliTaq Gold from Applied Biosystems
(Courtaboeuf, France) with the CG Forward and CG Reverse primers
[20] to obtain the CGB insert. The PCR products were puriﬁed by
electrophoresis on 1% agarose gel using the S.N.A.P. gel puriﬁcation
kit from Invitrogen (Cergy Pontoise, France). Next, the inserts and
pcDNA3 plasmid (Invitrogen) were digested with XbaI from New
England Biolabs (Frankfurt, Germany) overnight at 37 °C and 19 pmol
of plasmid was dephosphorylated using 0.4 units of calf intestinal
alkaline phosphatase from Promega (Charbonnières-les-bains, France)
following the manufacturer's instructions. After precipitation and
ligation of the digested products, sequences were cloned using the
TOP10F' chemically competent E. coli from Invitrogen following the
manufacturer's instructions. Fragments were directly sequenced with
sequencing primers T7 and Sp6 together with the hCG Forward
and hCG Reverse primers using the ABI PRISM Dye Terminator Cycle
Sequencing Reaction Kit (PE Biosystems, Courtaboeuf, France) on an
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cations. Primers were: CG Forward: 5′-TGTGCTCTAGATCATGACCAAG
GATGGAGATGTTCCAG-3′; CG Reverse: 5′-GCACAGTCTAGATTATTGTG
GGAGGATCGGG-3′; T7 (forward): 5′-TAATACGACTCACTATAGGG-3′;
and Sp6 (reverse): 5′-GATTTAGGTGACACTATAG-3′.
2.7. Immunocytochemical studies
Indirect immunoperoxidase staining of ﬁxed and permeabilized
cells was performed using monoclonal antibodies FB12 and FBT11-II
or MG100 IgG1 isotype control (Invitrogen). For immunocytochemical
studies on cell lines, cells were grown in a permanox Lab-Tek chamber
slide (nunc, Thermo Fisher Scientiﬁc, Brebières, France), ﬁxed in 4%
PFA in PBS for 20min at room temperature (RT) and then permeabilized
in methanol for 8 min at −20 °C. Slides were then either stained
immediately or stored at−80 °C. Antibodies were diluted at 5 μg/ml
in 1% BSA in PBS and staining was performed using the NovoLink
detection system kit (A. Menarini diagnostics, Rungis, France) following
the manufacturer's instructions. Between steps, slides were washed
twice for 5 min in 50 mM TBS pH 7.6 and once in TBS-0.1% Tween 20.
Cells were counterstained with Harris hematoxylin.
2.8. Immunohistochemical studies
For immunohistochemical studies on placentas, placental tissue of
ﬁrst trimester (8 to 12 WA; n = 3) or second trimester (16 to 19 WA;
n = 4) pregnancy was obtained from legal abortion while placental
samples from late pregnancy (39 WA; n = 1) were obtained at term
from uncomplicated pregnancies. Use of tissues was approved by the
local ethical committee. Tissues obtained were ﬁxed in 4% buffered
neutral formalin, dehydrated and embedded in parafﬁn. Sections, 5 to
6 μm in thickness, were deparafﬁnized, followed by standard histologi-
cal techniques. Antibodies were diluted in 1% BSA in PBS and staining
was performed using the NovoLink detection system kit (A. Menarini
diagnostics, Rungis, France) following the manufacturer's instructions.
Between steps, slides were washed twice in 50 mM TBS pH 7.6 for
5 min and once in TBS-0.1% Tween 20. Cells were counterstained with
Harris hematoxylin.
2.9. Development of immunoassays
i) An enzyme linked immunosorbent assay (ELISA) was performed
with Maxisorp nunc plates (Thermo Fisher Scientiﬁc, Brebières,
France) coated with 0.75 μg of monoclonal antibody FB09 and/or
0.25 μg of monoclonal antibody FB12 in 0.1 M phosphate buffer
pH 7.4, blockedwith 1% bovine serum albumin in PBS and incubated
with the hCGβ standards (CIS Bio International, France; 1 ng
CIS = 1 mIU 1st IRP WHO 75/551) for 1 h at 37 °C. Bound hCGβ
was detected with monoclonal antibody FBT11-II, coupled with
biotin, for 1 h at 37 °C (Biotin Labeling Kit-NH2 from Interchim,
Montluçon, France). The platewas then incubatedwith Immunopure
Streptavidin Horseradish Peroxidase conjugated (Pierce, Thermo
Fisher Scientiﬁc, Brebières, France) for 15 min at RT. One-Step
Ultra TMB-ELISA from Thermo Scientiﬁc was used as the substrate
and the absorbance was read at 450 nm. Experiments were done in
duplicate. The standard curve was constructed with the hCGβ
standards used at increasing concentrations ranging from 0.1 to
47 ng/ml. Linearity was consistently shown in between run assays.
ii) A sandwichmagnetic immunoassay (MIA) was developed following
the guidelines previously described [21]. Seventy percent-porosity
synthetic-polymer-ﬁber-based cylindrical wicks (Filtrona, Reinbek,
Germany) were used as solid-phase supports. After washing with
excess absolute ethanol and then 50% ethanol, each wick was coated
with 2.5 μg of monoclonal antibody FB09 and 2.5 μg of monoclonal
antibody FB12 in phosphate buffer pH 7.4. These solid phases were
then inserted in MIAﬂo cartridges (Magnisense, Paris, France).In parallel, 200 nm-diameter carboxyl-modiﬁed superparamagnetic
beads referred to as Estapor M1-020/50 (Merck Chimie, Fontenay
sous bois, France) were coated with monoclonal antibody FBT11-II
(50 mg/g) according to the manufacturer's instructions. They were
then mixed with hCGβ standards to allow conjugation between
hCGβ and the FBT11-II-covered magnetic beads. The mixture, con-
taining 24 μg of magnetic beads per cartridge, was immediately
passed back and forth through FB09 and FB12 coated-MIAﬂo
cartridges a number of times for a total incubation time of 14 min.
After four washings with a phosphate buffer containing 0.1% tween
to remove unbound magnetic beads, MIAﬂo cartridges were mea-
sured by means of a MIAtek reader (Magnisense, Paris, France). A
magnetic signal is recorded by the reader at a voltage frequency
which is a linear combination of two excitation frequencies preset
by the readermanufacturer. This signal is proportional to the amount
of magnetic material present in the cartridges, thus to the number of
sandwiched magnetic beads. Microplates (96-well) were used to
hold reagents and washing solutions, to mix HGCβ standards and
magnetic beads, and to collect waste. Experiments were performed
in duplicate. The standard curvewas constructedwith 100 μl samples
of hCGβ at concentrations ranging from 0.21 to 23.2 ng/ml.
3. Results
3.1. Competitive inhibition assays with synthetic peptides show speciﬁc
recognition of type II hCGβ by FBT11-II
Type I and type II genes were described based on the residue differ-
ence in position 117 [6,10,11]. Interestingly, apart from the difference in
amino acid 117, two other amino acids differ between type I and type II
gene products: Arg2 andMet4 for type I as opposed to Lys2 and Pro4 for
type II [7,10,22] (Fig. 1A). Since it was previously shown that FBT11-II
recognizes residues 1 through 7 and residues 82 through 92 of the
free hCGβ subunit [16] (Fig. 1B), we examined whether binding of
FBT11-II was sensitive to the differences in the N-terminal sequence of
hCGβ. To determinemAb FBT11-II's speciﬁcity,we performed inhibition
assays with synthetic peptides spanning residues 1 through 7.We used
three peptides analogous to sequences 1–7 of hCGβ encoded by type I
gene (SREMLRP), 1–7 of hCGβ encoded by type II genes (SKEPLRP)
and 1–7 of LHβ (SREPLRP). The results are shown in Fig. 2. First, we
determined the dilution of FBT11-II which produced a 50% binding to
125I-hCGβ in the absence of peptide. Then, competitive inhibition assays
were performed with the deﬁned dilution of antibody. Displacement
curves were generated in the presence of increasing concentrations of
unlabeled peptides.
Synthetic peptide SKEPLRP, corresponding to theN-terminal sequence
encoded by type II genes, exhibited the highest potency in displacing
bound 125I-hCGβ from antibody FBT11-II. In striking contrast, peptide
SREMLRP, differing only in two residues and corresponding to the
N-terminal sequence encoded by the type I gene, was unable to inhibit
the binding of the β-subunit to antibody FBT11-II. Peptide SREPLRP,
corresponding to the 1–7 N-terminal sequence of LHβ and comprising
only one residue change compared to the type II sequence, was able to
inhibit binding of hCGβ to FBT11-II to a lesser degree than SKEPLRP. As
FBT11-II displays a very low cross reactivity (0.6%) with LHβ [14], these
observations, taken all together, demonstrate that FBT11-II binds with a
high speciﬁcity to hCGβ encoded by type II genes.
3.2. Sequencing of hCGβ genes
In order to conﬁrm that monoclonal antibody FBT11-II is speciﬁc for
the hCGβ subunit encoded by type II genes (referred to as type II hCGβ),
we selected cell lines that express either type I or type II genes as
model systems. Human choriocarcinoma cell line JEG-3 expresses
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Fig. 1.The human chorionic gonadotropin beta subunit. A)Organization of the CGβ/LHβ gene cluster and amino acid sequences of expressed genes. Only genes CGβ3, CGβ5, CGβ7 and CGβ8
code for the hCGβ subunit. Type I gene codes for amature protein with an arginine residue at amino acid 2, amethionine residue at amino acid 4 and an alanine residue at amino acid 117.
Type II genes encode a mature protein with a lysine residue at amino acid 2, a proline residue at amino acid 4 and an aspartic acid at amino acid 117. Also shown is the LHβ gene, which
encodes amature LHβ proteinwith an arginine residue at amino acid 2, a proline residue at amino acid 4 and a glycine residue at amino acid 117. B) Localization of FBT11-II epitopes on the
crystal structure of hCG. hCG is shown as a ribbon diagram(ProteinData Bank IDPDB: 1HRP) [44]. The alpha subunit is represented in blue and the beta subunit is represented in green. The
discontinuous epitope recognized by mAb FBT11-II spans residues 1-7 and 82-92 and is indicated by black spheres, residues 2 and 4 are shown in green. As a comparison, type I hCGβ is
shownwith residues 2 and 4 indicated by red spheres, emphasizing the difference between type I and type II proteins concerning the FBT11-II epitope. Residue 1, while not appearing on
the crystal structure, has been added for clarity. This image was obtained using the program Swiss-PdbViewer (http://www.expasy.org/spdbv/) [45].
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as prototypic of cell lines expressing type II hCGβ. It was initially
described that the bladder cell line T24 expressed only the type I gene
[2]. However, it was later argued that this cell line expressed only type
II genes [13]. In order to clarify this issue, we sequenced the CG beta
genes encoded by T24 cell line. The CGB mRNA of human bladder
carcinoma cell line T24was ampliﬁed byRT-PCR, cloned and sequenced.
Our results show that T24 cell line transcribes only the β7 gene (type I
CGB gene) (Fig. 3). We conﬁrmed this result by quantitative real-time
PCR as shown in [24].
3.3. FBT11-II speciﬁcally recognizes type II hCGβ in a cellular setting
In order to determine whether mAb FBT11-II speciﬁcally recognizes
type II hCGβ in a cellular setting, detection of hCGβ on either humanchoriocarcinoma cell line JEG-3 or human bladder carcinoma cell line
T24 was performed by immunocytochemistry using either mAb FB12,
mAb FBT11-II or IgG1 isotype control at 5 μg/ml. Representative results
are shown in Fig. 4. Monoclonal antibody FB12, directed against the
110–116 region, is speciﬁc for hCG and hCGβ, and its binding to hCGβ
is unaffected by the presence of an alanine residue instead of an aspartic
acid residue at position 117 [18]. Thus, FB12 recognizes both type I and
type II hCGβ. Monoclonal antibody FBT11-II is speciﬁc for free hCGβ and
had never before been tested for its speciﬁc recognition of either type I
or type II hCGβ.
As expected, FB12 recognized type II hCGβ expressed by the JEG-3
cell line as well as type I hCGβ expressed by the T24 cell line (Fig. 4,
left panels). In contrast, FBT11-II only reacted with hCGβ produced by
the JEG-3 cell line indicating that this antibody speciﬁcally recognizes
type II hCGβ (Fig. 4, center panels). Immunocytochemical analyses
%
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Fig. 2. Inhibition of 125I-hCGβ binding to monoclonal antibody FBT-11-II by synthetic
peptides corresponding to residues 1 through 7 of type I gene (triangles), type II genes
(squares) or LHβ (circles).
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right panels). Both FB12 and FBT11-II showed a heterogeneous staining
of JEG-3 cells, whichwas also observedwith polyclonal antibody A0231,
directed to hCG, and on different batches of JEG-3 cell lines (data not
shown).
3.4. FBT11-II recognizes type II hCGβ produced by trophoblasts during the
course of gestation
In order to conﬁrm that FBT11-II is able to recognize type II hCGβ
produced by normal trophoblasts during the course of gestation, we
performed immunohistochemical staining on different placenta sam-
ples (Fig. 5). In situ detection of either hCG or hCGβ was performed
using mAb FB12, which recognizes both type I and type II hCGβ. In
early placenta obtained at 9 weeks (Fig. 5, top row), immunostaining
with FBT11-II was exclusively localized to syncytiotrophoblast (ST),
whereas FB12 stained either both the cytotrophoblast (CT) and the
ST or only the ST, depending on the individual villous structures. In
the case of mid-term placenta (17 weeks) (Fig. 5, middle row), the
cytological localization of type II hCGβ was similar to that in early
placenta, but the staining intensity was less prominent. Interestingly,
immunostaining with FB12 at this term was exclusively localized
to the ST. In term placenta obtained at 39 weeks of gestation, both
immunostaining with FBT11-II and FB12 were observed in the
syncytiotrophoblast (Fig. 5, bottom row). Staining with a normal
mouse IgG1 isotype control was consistently negative in all samples.
3.5. Development of immunoassays speciﬁc for type II hCGβ
FBT11 is already used in a commercial immunoradiometric assay
(ELSA-FbHCG). In order to design alternative, radioactive free assays
that speciﬁcally detect type II hCGβ, we developed an ELISA usingT24 (TYPE I) TCCAGGGAGATGCT
JEG (TYPE II) TCCAAGGAGCCGCT
426
T24 (TYPE I) SerArgGluMetLe
JEG (TYPE II) ---Lys---Pro--
CGβ mRNA
Fig. 3. Schematic representation of the oligonucleotide sequence corresponding to residu
Sequence: NM_033043.1). Codon differences are underlined and the corresponding amin
to the T24 sequence are shown. Data were obtained from three independent experimentsFBT11-II as indicator antibody. In previous radiolabeled antibody
binding experiments based on immunoradiometric assays (IRMAs), it
was demonstrated that enhanced binding of indicator antibody to hCG
was obtained using anti-C terminal peptide (CTP) antibodies FB09 and
FB12 as capture antibodies [18]. In order to determine whether this
synergistic effect for capturing hCGmight also be observed for detecting
type II hCGβ, an enzyme linked immunosorbent assay (ELISA) was
designed. This assay uses mAbs FB09 and FB12, either alone or in
combination, to capture hCGβ on a solid phase support, and biotinylated
mAb FBT11-II as indicator antibody (Fig. 6A, right). Neither at a lowdose
(9.8 ng/ml) nor at a high dose of hCGβ (47 ng/ml), was any signiﬁcant
binding of hCGβ to FB09 detected, whereas hCGβ showed low level
binding to FB12 at 47 ng/ml (Fig. 6A, left). By using both FB09 and
FB12 as capture antibodies (50%, vol/vol), a dramatic synergistic effect
was observed with a 20-fold increase of hCGβ-bound signal detected
at 47 ng/ml.
Based on these results, this ELISA was further developed. An hCGβ
standard curve is shown in Fig. 6B. The minimum detectable dose of
hCGβ (analytical sensitivity) was determined to be 0.15 ng/ml. This
assay was used to measure type II hCGβ in culture supernatants of
JEG-3 and T24 cell lines. Using an assay based on mAb FBT10 both
these cell lines were shown to secrete the hCGβ subunit [2]. However,
since mAb FBT10 does not distinguish between type I and type II
hCGβ [2], we were up to now unable to dose type II gene expression.
Using the newly developed ELISA based on FBT11-II we were able to
determine that concentrated supernatants from JEG-3 cells contained
hCGβ type II (32 ng/ml ±1.6, mean and SEM) while no type II hCGβ
was detected in concentrated T24 supernatants. In order to improve
the analytical sensitivity of immunoassays, we used a novel technique
named magnetic immunoassay or MIA based on the highly sensitive
detection of a magnetic signal [21]. This MIA showed an analytical
sensitivity lower than 0.2 ng/ml (Fig. 6C). Serum levels of type II hCGβ
were measured by ELISA in patients with nontrophoblastic neoplasms
including bladder and lung cancers as representative examples. Low
levels of type II hCGβ were detected as illustrated in Fig. 6D and E. In
sera from healthy male and cycling, non-pregnant, female individuals
hCGβ levels were consistently below 0.1 ng/ml (data not shown). In
addition, levels of type II hCGβ were also measured during the ﬁrst
trimester of pregnancy in maternal serum from women with fetal
Down syndrome and, as expected, high levels of type II hCGβ were
observed (Fig. 6F).
4. Discussion
The main goal of this study was to determine whether an assay can
speciﬁcally distinguish between hCGβ encoded by type I and type II CGB
genes (type I and type II hCGβ). It is noteworthy that type I and type II
hCGβ differ in their amino acid sequences at positions 2, 4 and 117
(Fig. 1) and that these differences might generate different epitopes.
The hCGβ subunit contains at least 13 epitopes, named β1 to β13, of
which β1 to β5 are exposed on the hCG heterodimer and β6 and β7TCGG TTCCAGGCCTCC
TCGG TTCCAGGACTCC
443
uArg PheGlnAlaSer
---- ------Asp---
768 790
es 2, 4 and 117 of the T24 cell line compared to the JEG-3 cell line (NCBI Reference
o acid residues are indicated below. For JEG-3, only the amino acids that are different
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Fig. 4. Immunocytochemical staining of human choriocarcinoma cell line JEG-3 (top row) and human bladder carcinoma cell line T24 (bottom row) with hCGβ speciﬁc antibodies FB12
(left), FBT11-II (center) or normal mouse IgG1 control (right). Cells were counterstained with hematoxylin.
97L. Aldaz-Carroll et al. / Clinica Chimica Acta 444 (2015) 92–100are speciﬁc for free hCGβ [25,26]. Linear epitopes β8 and β9 have been
mapped to residues 109–145, which constitute the C-terminal peptide
(CTP) of hCGβ and contain residue 117, but all other epitopes are
discontinuous.
Since monoclonal antibody FBT11 is speciﬁc to free hCGβ and binds
to a discontinuous epitope comprising residues 1 through 7 and 82
through 92 [14,15], we aimed to determine whether its derivative,
FBT11-II, could differentiate between type I and type II hCGβ. Competi-
tive inhibition assays with peptides show that FBT11-II recognizes the
amino terminal sequence corresponding to type II hCGβ while it does
not bind to the amino terminal sequence corresponding to type I hCGβ.9-
w
ee
k
17
-w
ee
k
39
-w
ee
k
S
ST
ST CT
CT
CT
FB12 FBT1
ST
Fig. 5. Immunocytochemical localization of hCGβ inﬁrst, second and third trimester placentas. F
39-week (bottom) placenta were stained with hCGβ speciﬁc antibodies FB12 (left), FBT11-II (c
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shown. Insets: higher magniﬁcation images of boxed regions. Scale bars represent 50 μm.FBT11-II is therefore directed against a highly speciﬁc and discontinuous
epitope of hCGβ that does not belong to theβ1 toβ13epitopespreviously
described and that we have called β14. This β14 epitope comprises two
regions: region 1–7, with a lysine and a proline residue at positions 2
and 4 respectively, and region 82–92, and is only present in type II
hCGβ. To conﬁrm that FBT11-II speciﬁcally recognizes type II gene
expression, T24 and JEG-3 cells were used as prototypic cells expressing
hCGβ encoded by either type I or type II genes, respectively. Sequencing
of CGB genes conﬁrmed that the bladder cell line T24 expresses type I
gene β7. Previous reports have shown that tumor progression in bladder
tissues is characterized by different patterns of transcription of theT
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Fig. 6. Speciﬁc type II hCGβ immunoassays. A) Left: binding of biotinylated FBT11-II to hCGβ immobilized on an ELISA plate by anti-CTP antibodies FB09 and FB12 either alone or in
combination. Data are mean results (±SEM) of three independent experiments and are expressed in optical density (OD). Two different concentrations of hCGβ were used: 9.8 ng/ml
(indicated in dark green) and 47 ng/ml (indicated in light green). Right: schematic representation of the hCGβ capture method developed here. This assay uses two antibodies as capture
antibodies, FB09 and FB12, while biotinylated antibody FBT11-II is used as indicator. B: biotin; S: streptavidin; HRP: horseradish peroxidase. B) Standard curve of the ELISA formean values
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C) Standard curve of the sandwich magnetic immunoassay (MIA) for mean values of hCGβ detected using mAbs FB09 and FB12 as capture antibodies and FBT11-II conjugated to
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and early-stage non-invasive papillary carcinoma tumors (stage Ta)
whereas, in addition to β7, type II genes were transcribed in more
advanced tumors (stages T1 to T4) [27]. Thus, it was not unexpected
that a bladder cell line preferentially expresses type I gene. Once type I
gene expression was conﬁrmed in T24 cells, immunocytochemistry
assays were used to determine whether FBT11-II speciﬁcally detects
type II hCGβ. We found that FBT11-II does not recognize type I hCGβ,
expressed by T24 cells, and only recognizes type II hCGβ, expressed by
JEG-3 cells. Lastly, immunohistochemical staining was carried out on
placentas at different times of gestation, showing that FBT11-II consis-
tently stains the syncytiotrophoblast as previously observed [28]. As
normal trophoblastic cells express type II genes, these results are in line
with previous observations.The measurement of hCG protein or its variants is important for
monitoring pregnancy, for prenatal screening for Down syndrome and
for the diagnosis or follow-up of tumors [29,30]. Type I hCGβ is prefer-
entially expressed by cells of nontrophoblastic origin, whereas tropho-
blastic and malignant nontrophoblastic tissues also express type II
hCGβ. The expression of type I gene by numerous normal tissues
might hinder the speciﬁc recognition of hCGβ expressed during preg-
nancy. As the measurement of hCGβ is useful for the screening for
Down syndrome during the ﬁrst trimester, it would be preferable to
screen for this chromosomal abnormality by using an assay speciﬁc for
type II hCGβ. As we show in this study, this is already the case for the
immunoradiometric assay ELSA-FbHCG (by CIS, UK) used by Spencer
et al., in their clinical trials [31]. This assay is based on FBT11, which is
the parental clone from which FBT11-II is derived. Since FBT11-II
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the assay used by Spencer and colleagues may owe its high detection
rate of Down syndrome and low false positive cases to the speciﬁc
detection of hCGβ of trophoblastic origin (type II) without cross-
reaction with hCGβ of nontrophoblastic origin (type I).
Different variants of hCG have been described, including carbohy-
drate isoforms, nicked variants and truncated versions of the proteins
and of individual subunits. Part of the hCG in urine, as well as its free
β-subunit, has intrachain nicks at various positions between amino
acids 44 and 48. These forms may also occur in the serum of cancer
patients and in patients with trophoblastic disease [32–34]. Antibodies
have been obtained againstmost of these variants and are used routinely
in immunoassays. However, recent reports have demonstrated that
because of hCG's heterogeneity, different immunoassays give differing
results for the same specimens [35]. The data obtained from these tests
can differ depending on the epitopes and isoforms recognized by the
antibodies, for example depending on their sensitivity to the nicked
form [15,25].
It is important to know the speciﬁcity of the method being used as
pregnancy and cancer studies require different speciﬁcations. Indeed,
during pregnancy, the predominant form of hCG in serum is intact
hCG, whereas patients with gestational trophoblastic disease secrete
intact hCG, free hCGβ, nicked hCG and nicked hCGβ [29]. Individuals
harboring nongestational trophoblastic neoplasms, such as germ cell
tumors of the testes and ovaries, frequently secrete hCGβ and lesser
amounts of hCG, while patients with nontrophoblastic neoplasms
secrete only hCGβ. Adding to this complexity, two different hCGβ
subunits produced by cells of different origin have several amino acid
changes, depending upon the genes expressed by these cells. The type
I gene is preferentially expressed by cells of nontrophoblastic origin,
whereas trophoblastic and malignant nontrophoblastic tissues also
express type II genes. hCGβ expressed by type I or II genes differs in
three residues located in positions 2, 4 and 117 (Fig. 1). Up to now,
our team and others have tried to distinguish between type I and type
II expression by focusing on residue 117. Indeed, these types of studies
have concentrated on elegant techniques using molecular beacons or
nested PCR and able to detect a single nucleotide difference at position
117, i.e. GCC as opposed to GAC coding respectively for alanine or
aspartic acid [2,13]. However, depending upon the techniques, different
results were observed in tissues and in cell lines as the T24 bladder cell
line [2,13]. Moreover, these techniques did not exploit the N-terminal
differences between type I and type II genes. In addition, a speciﬁc
antibody able to distinguish between the free hCGβ subunits tran-
scribed and translated from either type I or type II genes has never
been described: fusion experiments using synthetic peptides analogous
to the 114–122 region of hCGβ as immunogens and aimed at generating
monoclonal antibodies capable of distinguishing an aspartic acid from
an alanine at position 117 have been unsuccessful, at least in our labora-
tory. Thanks to FBT11-II, which binds to a discontinuous epitope com-
prising residues 1 through 7 and 82 through 92, we can now address
the challenge of distinguishing type I from type II hCGβ using the
differences located in the N-terminal end.
In order to speciﬁcally and easily detect type II hCGβwithout using
radioactive reagents, an ELISA and a magnetic immunoassay (MIA)
were developed. These tests should allow us to discriminate between
type I and type II expression. Both immunoassays are based on FB09
and FB12 mAbs directed to the carboxyl terminal portion of hCGβ as
capture antibodies and on mAb FBT11-II as a tracer antibody binding
only to type II hCGβ. The ELISA underlines the synergistic effects of
FB09 and FB12 to capture hCGβ while both the ELISA and MIA display
the required sensitivity to detect low amounts of type II hCGβ in clinical
settings. To our knowledge, the current study is the ﬁrst to describe
an assay speciﬁc for type II beta subunit. This assay can be useful to
determine the presence or absence of type II hCGβ in biological ﬂuids.
As a proof of concept, ELISA for type II hCGβwas performed on sera col-
lected during theﬁrst trimester of pregnancy fromwomen affectedwithfetal Down syndrome and on sera from patients with nontrophoblastic
neoplasms. High levels of type II hCGβwere present in sera from Down
syndrome pregnancies (Fig. 6F) while low levels were detected in sera
from patients with lung and bladder cancers (Fig. 6D).
Recently, it was stated that even though most hCG assays are very
reliable, there is still a need for better methods for diagnosis and moni-
toring of cancers [35]. Methods that detect type II hCGβmight respond
to this need as it has been shown that type II genes are expressed in
many nontrophoblastic malignancies including lung, thyroid, prostate,
bladder and breast cancers [27,36–39]. In invasive bladder cancers,
type II genes are predominantly expressed. In breast cancers, expression
of type II genes has prognostic value for relapse-free survival. Moreover,
it is well established that the more malignant forms of gestational
trophoblastic diseases express excessive amounts of hCGβ [29] and
that gonadal tumors might also express hCGβ. Thus, it would be useful
to monitor patients with trophoblastic and nontrophoblastic tumors
for the presence of type II hCGβ in biological ﬂuids. As a representative
example, Fig. 6E shows the monitoring of a patient with a lung cancer
based on serum levels of type II hCGβmeasured by ELISA.
Finally, it remained unclear why some men and women show posi-
tive in hCG screening tests when they are not pregnant, do not have
cancer and are otherwise asymptomatic. In linewith these observations,
the group of Laurence Cole described a genetic defect designated
“Familial hCG Syndrome” [40,41]. Members of families with inherited
Familial hCG Syndrome produce only hCGβ, and hCG or hCGβmissing
the β-subunit-C-terminal peptide. Of these molecules, 48 to 100%
were described as missing the C-terminal peptide [42]. Taking together
his observations and our ﬁndings, Laurence Cole elegantly suggests
that men and women with unexpected positive hCG screening tests,
including individuals with “Familial hCG syndrome”, that produce
what they had named “hCGβ missing the β-subunit-C-terminal pep-
tide” may in fact produce hCGβ encoded by CGB7 gene which would
therefore not be detected by assays using FBT11 or FBT11-II. This
seems to be supported by the fact that hCGβ missing the C-terminal
peptide appears to have a normal β-subunit size by gel ﬁltration [42].
Thus assays speciﬁc for both type II hCGβ and the C-terminal peptide,
as are the ELISA and MIA assays based on FBT11-II, FB09 and FB12
antibodies, might help to measure hCGβ produced only by pregnant
women and patients with cancer since these assays would not detect
hCGβ produced by patients with Familial hCG Syndrome and encoded
by the type I gene. This type of selectivity can prove useful in avoiding
unnecessary chemotherapy of Familial hCG Syndrome patients before
diagnosis, as what happened to two of the ﬁfteen reported cases [40].
A different and altogether unexpected application of these assays
could be found in the world of sports. Up to now, athletes with Familial
hCG Syndrome were wrongly accused of doping with hCG (as was the
case of ﬁve of the ﬁfteen reported cases) since current tests do not
differentiate between type I and type II hCGβ [42]. It is possible that
using a type II speciﬁc assay would allow the doping agencies to avoid
detecting cases of Familial hCG Syndrome.
Eighty-seven years after the ﬁrst description of an hCG assay by
Ascheim and Zondek [43], the speciﬁc recognition of type II hCGβ
might continue to improve the clinical usefulness of such assays.
Declaration of authors' roles
L Aldaz-Carroll: acquisition of data; analysis and interpretation of
data; drafting of the manuscript.
S Richon: acquisition of data; analysis and interpretation of data;
technical and material support.
V Dangles-Marie: critical discussion.
M Cocquebert: technical and material support; critical discussion.
T Fournier: technical andmaterial support; critical discussion; critical
revision of the manuscript for important intellectual content.
F Troalen: acquisition of data; analysis and interpretation of data;
technical and material support.
100 L. Aldaz-Carroll et al. / Clinica Chimica Acta 444 (2015) 92–100D Stevens: analysis and interpretation of clinical data.
B Guery: technical and material support.
A-M Hersant: technical and material support.
A Nordor: critical discussion; critical revision of the manuscript.
J Guibourdenche: analysis and interpretation of clinical data.
A Pecking: critical discussion; obtained funding.
D Bellet: study concept, design and supervision; analysis and inter-
pretation of data; critical revision of themanuscript for important intel-
lectual content; obtained funding.
Funding
This work was supported by Geneviève and Jean-Paul Driot, Sally
Paget-Brown, Philippe, Laurent and Stéphanie Bloch, Ouidad Hachem
Foundation grant 03015 and Association pour la Recherche en
Cancérologie de Saint-Cloud (ARCS) grant 22313.
Conﬂict of interest
Co-authors have no conﬂict of interest to declare.
Acknowledgments
We are grateful to Jean-Jacques Candelier and Philippe Coullin for
immunostaining support, to Luc Lenglet and Sebastien Quesney from
Magnisense for invaluable assistance on magnetic immunoassays and
to Josette Badet for helpful discussions.
We thank also the Cellular and Molecular Imaging Platform, CRP2,
UMS 3612 CNRS, US25 INSERM-IRD, Université Paris Descartes for
technical support during the acquisition of immunocytochemistry and
immunohistochemistry images.
References
[1] Stenman UH, Tiitinen A, Alfthan H, Valmu L. The classiﬁcation, functions and clinical
use of different isoforms of HCG. Hum Reprod Update 2006;12:769–84.
[2] Bellet D, Lazar V, Bieche I, et al. Malignant transformation of nontrophoblastic cells is
associated with the expression of chorionic gonadotropin beta genes normally
transcribed in trophoblastic cells. Cancer Res 1997;57:516–23.
[3] Marcillac I, Troalen F, Bidart JM, et al. Free human chorionic gonadotropin beta
subunit in gonadal and nongonadal neoplasms. Cancer Res 1992;52:3901–7.
[4] Fiddes JC, Goodman HM. The gene encoding the common alpha subunit of the four
human glycoprotein hormones. J Mol Appl Genet 1981;1:3–18.
[5] Boorstein WR, Vamvakopoulos NC, Fiddes JC. Human chorionic gonadotropin beta-
subunit is encoded by at least eight genes arranged in tandem and inverted pairs.
Nature 1982;300:419–22.
[6] Fiddes JC, Goodman HM. The cDNA for the beta-subunit of human chorionic
gonadotropin suggests evolution of a gene by readthrough into the 3′-untranslated
region. Nature 1980;286:684–7.
[7] Rull K, Nagirnaja L, Ulander VM, et al. Chorionic gonadotropin beta-gene variants
are associated with recurrent miscarriage in two European populations. J Clin
Endocrinol Metab 2008;93:4697–706.
[8] Rull K, Hallast P, Uuskula L, et al. Fine-scale quantiﬁcation of HCG beta gene tran-
scription in human trophoblastic and non-malignant non-trophoblastic tissues.
Mol Hum Reprod 2008;14:23–31.
[9] Hallast P, Rull K, Laan M. The evolution and genomic landscape of CGB1 and CGB2
genes. Mol Cell Endocrinol 2007;260–262:2–11.
[10] Policastro P, Ovitt CE, Hoshina M, Fukuoka H, Boothby MR, Boime I. The beta subunit
of human chorionic gonadotropin is encoded by multiple genes. J Biol Chem 1983;
258:11492–9.
[11] Talmadge K, Vamvakopoulos NC, Fiddes JC. Evolution of the genes for the beta
subunits of human chorionic gonadotropin and luteinizing hormone. Nature 1984;
307:37–40.
[12] Hallast P, Nagirnaja L, Margus T, Laan M. Segmental duplications and gene conver-
sion: human luteinizing hormone/chorionic gonadotropin beta gene cluster.
Genome Res 2005;15:1535–46.
[13] Span PN, Thomas CM, Heuvel JJ, et al. Analysis of expression of chorionic gonadotro-
phin transcripts in prostate cancer by quantitative Taqman and a modiﬁed molecu-
lar beacon RT-PCR. J Endocrinol 2002;172:489–95.
[14] Bidart JM, Troalen F, Lazar V, et al. Monoclonal antibodies to the free beta-subunit of
human chorionic gonadotropin deﬁne three distinct antigenic domains and distin-
guish between intact and nicked molecules. Endocrinology 1992;131:1832–40.[15] Kardana A, Cole LA. Polypeptide nicks cause erroneous results in assays of human
chorionic gonadotropin free beta-subunit. Clin Chem 1992;38:26–33.
[16] Bidart JM, Troalen F, Salesse R, Bousﬁeld GR, Bohuon CJ, Bellet DH. Topographic
antigenic determinants recognized by monoclonal antibodies on human choriogo-
nadotropin beta-subunit. J Biol Chem 1987;262:8551–6.
[17] Ozturk M, Bellet D, Manil L, Hennen G, Frydman R, Wands J. Physiological studies of
human chorionic gonadotropin (hCG), alpha hCG, and beta hCG as measured by
speciﬁc monoclonal immunoradiometric assays. Endocrinology 1987;120:549–58.
[18] Bellet DH, Ozturk M, Bidart JM, Bohuon CJ, Wands JR. Sensitive and speciﬁc assay for
human chorionic gonadotropin (hCG) based on anti-peptide and anti-hCGmonoclo-
nal antibodies: construction and clinical implications. J Clin Endocrinol Metab 1986;
63:1319–27.
[19] Fraker PJ, Speck Jr JC. Protein and cell membrane iodinationswith a sparingly soluble
chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res
Commun 1978;80:849–57.
[20] Shih IM, Torrance C, Sokoll LJ, Chan DW, Kinzler KW, Vogelstein B. Assessing tumors
in living animals through measurement of urinary beta-human chorionic gonado-
tropin. Nat Med 2000;6:711–4.
[21] Nikitin PI, Vetoshko PM, Ksenevich TI. Magnetic immunoassays. Sens Lett 2007;5:
296–9.
[22] Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science
2001;291:1304–51.
[23] Jameson JL, Lindell CM, Habener JF. Gonadotropin and thyrotropin alpha- and beta-
subunit gene expression in normal and neoplastic tissues characterizedusing speciﬁc
messenger ribonucleic acid hybridization probes. J Clin Endocrinol Metab 1987;64:
319–27.
[24] Cocquebert M, Berndt S, Segond N, et al. Comparative expression of hCG beta genes
in human trophoblast from early and late ﬁrst-trimester placentas. Am J Physiol
Endocrinol Metab 2012;303:E950–8.
[25] Berger P, Sturgeon C. Human chorionic gonadotropin isoforms and their epitopes:
diagnostic utility in pregnancy and cancer. Expert OpinMed Diagn 2008;2:1347–64.
[26] Berger P, Sturgeon C, Bidart JM, et al. The ISOBM TD-7Workshop on hCG and related
molecules. Towardsuser-oriented standardization of pregnancy and tumor diagnosis:
assignment of epitopes to the three-dimensional structure of diagnostically and com-
mercially relevant monoclonal antibodies directed against human chorionic gonado-
tropin and derivatives. Tumour Biol 2002;23:1–38.
[27] Lazar V, Diez SG, Laurent A, et al. Expression of human chorionic gonadotropin beta
subunit genes in superﬁcial and invasive bladder carcinomas. Cancer Res 1995;55:
3735–8.
[28] Maruo T, Ladines-Llave CA, Matsuo H, Manalo AS, Mochizuki M. A novel change in
cytologic localization of human chorionic gonadotropin and human placental
lactogen in ﬁrst-trimester placenta in the course of gestation. Am J Obstet Gynecol
1992;167:217–22.
[29] Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer.
Clin Biochem 2004;37:549–61.
[30] Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and
18. N Engl J Med 2003;349:1405–13.
[31] Spencer K, Carpenter P. Prospective study of prenatal screening for Down's
syndrome with free beta human chorionic gonadotrophin. BMJ 1993;307:764–9.
[32] Cole LA, Kardana A, Ying FC, Birken S. The biological and clinical signiﬁcance of nicks
in human chorionic gonadotropin and its free beta-subunit. Yale J Biol Med 1991;64:
627–37.
[33] Jacoby ES, Kicman AT, Laidler P, Iles RK. Determination of the glycoforms of human
chorionic gonadotropin {beta}-core fragment by matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry. Clin Chem 2000;46:1796–803.
[34] Kardana A, Elliott MM, Gawinowicz MA, Birken S, Cole LA. The heterogeneity of
human chorionic gonadotropin (hCG). I. Characterization of peptide heterogeneity
in 13 individual preparations of hCG. Endocrinology 1991;129:1541–50.
[35] Gronowski AM. Clinical assays for human chorionic gonadotropin: what should we
measure and how? Clin Chem 2009;55:1900–4.
[36] Bieche I, Lazar V, Nogues C, et al. Prognostic value of chorionic gonadotropin beta
gene transcripts in human breast carcinoma. Clin Cancer Res 1998;4:671–6.
[37] Hotakainen K, Lintula S, Jarvinen R, et al. Overexpression of human chorionic gonad-
otropin beta genes 3, 5 and 8 in tumor tissue and urinary cells of bladder cancer
patients. Tumour Biol 2007;28:52–6.
[38] Span PN, Manders P, Heuvel JJ, et al. Molecular beacon reverse transcription-PCR of
human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in
breast cancer. Clin Chem 2003;49:1074–80.
[39] Yokotani T, Koizumi T, Taniguchi R, et al. Expression of alpha and beta genes of
human chorionic gonadotropin in lung cancer. Int J Cancer 1997;71:539–44.
[40] Cole LA. Familial HCG, syndrome. J Reprod Immunol 2012;93:52–7.
[41] Cole LA, Laidler LL. Inherited human chorionic gonadotropin. J Reprod Med 2010;55:
99–102.
[42] Cole LA, Butler S. Familial hCG syndrome: production of variable, degraded or
mutant forms of hCG. J Reprod Med 2014;59:435–42.
[43] Ascheim S, Zondek B. Das Hormon des Hypophysenvorderlappens: testobjekt zum
nachweis des hormons. Klin Wochenschr 1927;6:248–52.
[44] Lapthorn AJ, Harris DC, Littlejohn A, et al. Crystal structure of human chorionic
gonadotropin. Nature 1994;369:455–61.
[45] Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for
comparative protein modeling. Electrophoresis 1997;18:2714–23.
